Tupperware Brands Corp
Change company Symbol lookup
Select an option...
TUP Tupperware Brands Corp
AKRO Akero Therapeutics Inc
MRTX Mirati Therapeutics Inc
SIRC Solar Integrated Roofing Corp
CHSTY China High Speed Transmission Equipment Group Co Ltd
TTMZF Datable Technology Corp
WVFC W V S Financial Corp
WHLM Wilhelmina International Inc
SON Sonoco Products Co
VIRX Viracta Therapeutics Inc

Consumer Discretionary : Household Durables | Small Cap Value
Company profile

Tupperware Brands Corporation is a global consumer products company. The Company is engaged in the marketing, manufacturing and selling design-centric preparation, storage, and serving solutions for the kitchen and home through the Tupperware brand name. The Company primarily designs functional products to help store, serve, and prepare food. The Company operates its business through four geographic regions: Asia Pacific, Europe (Europe, Africa and the Middle East), North America, and South America. Its Tupperware brand product line consists of cookware, knives, microwave products, microfiber textiles, water-filtration-related items, and an array of products for on-the-go consumers. Its products include XtremAqua Freezable Bottle, Universal Cookware set, SuperSonic Choppers and others. The Company distributes its products into approximately 70 countries primarily through independent representatives around the world.

Day's Change
-0.27 (-5.71%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 23,531 shares is on pace to be much greater than TUP's 10-day average volume of 1,001,263 shares.


Moderna expects the shortage of its updated COVID-19 booster to soon be resolved

7:26 am ET September 22, 2022 (MarketWatch)

Jaimy Lee

Moderna still plans to deliver 70 million doses of its bivalent COVID-19 booster by the end of the year.

Moderna Inc. (MRNA) said Wednesday that it expects to resolve supply issues for its new COVID-19 booster "in the coming days."

Several media outlets reported this week that a shortage of Moderna's updated booster was the result of the U.S. Food and Drug Administration's ongoing inspection of a plant in Bloomington, Ind., that is operated by Catalent Inc. (CTLT). Moderna and Catalent set up an agreement back in 2020 to manufacture Moderna's COVID-19 vaccines.

The inspection has been completed, and the FDA on Tuesday allowed the 10 delayed batches of vaccine to ship, saying in a statement that "the agency has no concerns with the safety, effectiveness, or quality of these batches."

"We continue to see high demand in certain areas of the country," a Moderna spokesperson told MarketWatch in an email. "We anticipate that these availability constraints will be resolved in the coming days."

The company said it still plans to deliver 70 million doses of its bivalent COVID-19 booster by the end of the year. The updated booster -- called a bivalent shot -- protects against the original strain of the virus as well as the BA.4 and BA.5 subvariants of omicron.

The U.S. government so far has shipped more than 25 million doses of the new shots, primarily the bivalent vaccine developed by BioNTech SE (BNTX) and Pfizer Inc. (PFE), according to Reuters.

Other COVID-19 news to know:

-Jaimy Lee


(END) Dow Jones Newswires

September 22, 2022 07:26 ET (11:26 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.